Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

Nojomi
  IRCT20180725040596N2		 RCTumifenovir (arbidol)lopinavir/ritonavirCOVID 19 hospitalizedsome concern
50/50 inconclusive
    Chen_arbidol OBSumifenovir (arbidol)standard of careCOVID 19 hospitalizedcritical
    		37/121 inconclusive

      COVID 19 all comers meta-analysis

      ELACOI (Standard of care)
              NCT04252885      		 RCTumifenovir (arbidol)standard of careCOVID 19 all comerssome concern
      		16/7 inconclusive

        COVID-19 mild to moderate meta-analysis

        ELACOI (Lopinavir/ritonavir)
                  NCT04252885        		 RCTumifenovir (arbidol)lopinavir/ritonavirCOVID-19 mild to moderatesome concern
        		35/34 inconclusive
        • inconclusive 84 % increase in viral clearance by day 14 (PE) with a moderate degree of certainty due to some concern in risk of bias
        • inconclusive 8 % increase in viral clearance by day 7 (PE) with a moderate degree of certainty due to some concern in risk of bias

        PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
        Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

         

        - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons